When comparing the treatment groups to women without GDM, differences in metabolite profiles were also evident from the earliest point of measurement, many weeks before treatment; the Metformin and Insulin Groups already demonstrating an ‘unfavourable’, more insulin resistant profile, incorporating amongst other markers, higher total lipids in VLDL subclasses and larger VLDL particle size. Here, INS is linked to gestational diabetes.